Drug Profile
Cycloserine/lurasidone - NRx Pharmaceuticals
Alternative Names: Cyclurad; D-cycloserine/lurasidone.; Lurasidone/cycloserine; NRX-101Latest Information Update: 13 Feb 2024
Price :
$50
*
At a glance
- Originator NeuroRX
- Developer NeuroRX; NRx Pharmaceuticals
- Class Analgesics; Anti-infectives; Antidepressants; Antituberculars; Anxiolytics; Behavioural disorder therapies; Isoindoles; Isoxazoles; Piperazines; Small molecules; Thiazoles
- Mechanism of Action Cell wall inhibitors; Dopamine D2 receptor antagonists; Glycine gated NMDA receptor agonists; Serotonin 2A receptor antagonists; Serotonin 2C receptor antagonists; Serotonin 7 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Urinary tract infections
Highest Development Phases
- Phase III Bipolar depression
- Phase II/III Suicidal ideation
- Preclinical Pain; Post-traumatic stress disorders; Urinary tract infections
Most Recent Events
- 11 Feb 2024 NRx Pharmaceuticals plans a end of phase II meeting with US FDA
- 05 Feb 2024 Cycloserine/lurasidone - NRx Pharmaceuticals receives Breakthrough Therapy status for Pain in USA
- 22 Jan 2024 NRx pharmaceuticals completes enrolment in a phase IIb/III trial for bipolar depression (PO) (NCT03395392)